Scientific Highlights
1 – D. Vilasboas-Campos, J. H. Fernandes, M. D. Costa, J. Pereira-Sousa, J. Lopes, L. Costa-Meireles, B. Ferreira-Lomba, J. D. Da Silva, P. Maciel, A. Teixeira-Castro, PRO-FitS: a novel phenotypic assay to identify enhancers of proteostasis in C. elegans. [Preprint] (2026). https://doi.org/10.64898/2026.01.22.701023 .
2 – A. Silva, S. Duarte‐Silva, P. M. Martins, B. Rodrigues, D. Serrenho, D. Vilasboas‐Campos, A. Teixeira‐Castro, J. Vieyto‐Nuñez, J. Mieres‐Perez, F. Figueiredo, M. Podlasiak, T. Van‐der‐Kellen, J. Fraga, J. Noble, C. Lantz, N. Sepanj, D. Monteiro‐Fernandes, S. Guerreiro, A. Neves‐Carvalho, J. Pereira‐Sousa, F. Klärner, T. Schrader, J. A. Loo, A. Pastore, E. Sanchez‐Garcia, G. Bitan, A. L. Carvalho, P. Maciel, S. Macedo‐Ribeiro, Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies. Advanced Science, e02216 (2025). https://doi.org/10.1002/advs.202502216
3 – Duarte-Silva, S.*, Da Silva, J. D.*, Monteiro-Fernandes, D.*, Costa, M. D., Neves-Carvalho, A., Raposo, M., Soares-Cunha, C., Correia, J. S., Nogueira-Goncalves, G., Fernandes, H. S., Oliveira, S., Ferreira-Fernandes, A. R., Rodrigues, F., Pereira-Sousa, J., Vilasboas-Campos, D., Guerreiro, S., Campos, J., Meireles-Costa, L., Rodrigues, C. M. P., Cabantous, S., Sousa, S. F., Lima, M., Teixeira-Castro, A., & Maciel, P. (2024). Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of spinocerebellar ataxia type 3. The Journal of Clinical Investigation, 134(5), e162246. https://doi.org/10.1172/JCI162246
4 – L. Aguiar, L. Royon, R. Bastos-Gonçalves, T. Carvalho, E. Teixeira, A. Faria, A.V. Domingues, D. Vilasboas-Campos, R.M. Jungmann, N. Vasconcelos, L. Pinto, S. Fernandez, J. Barik, B. Coimbra, A. Rodrigues, Adaptive changes of cholinergic projections to the nucleus accumbens bidirectionally mediate cocaine reinforcing effects. [Preprint] (2025). https://doi.org/10.1101/2025.06.30.662309.
5 – R. Correia, A. V. Domingues, L. A. A. Aguiar, M. Cunha-Macedo, D. Vilasboas-Campos, N. Vieitas-Gaspar, R. M. Jungmann, E. Teixeira, B. Coimbra, A. J. Rodrigues, C. Soares-Cunha, Dissociable neuronal substrates for positive and negative valence stimuli in the nucleus accumbens. [Preprint] (2026). https://doi.org/10.64898/2026.01.24.701496.
6 – Raposo, M., Bettencourt, C., Melo, A. R. V., Ferreira, A. F., Alonso, I., Silva, P., Vasconcelos, J., Kay, T., Saraiva-Pereira, M. L., Costa, M. D., Vilasboas-Campos, D., Bettencourt, B. F., Bruges-Armas, J., Houlden, H., Heutink, P., Jardim, L. B., Sequeiros, J., Maciel, P., & Lima, M. (2022). Novel Machado-Joseph disease-modifying genes and pathways identified by whole-exome sequencing. Neurobiology of Disease, 162, 105578. https://doi.org/10.1016/j.nbd.2021.105578
7 – Costa, M. D., Da Silva, J. D., Almeida, D., Pereira-Sousa, J., Vilasboas-Campos, D., Fernandes, J. H., Teixeira-Castro, A., & Maciel, P. (2025). Differential effects of lifespan-extending genetic manipulations in an animal model of MJD/SCA3. Mechanisms of ageing and development, 225, 112064. https://doi.org/10.1016/j.mad.2025.112064
8 – Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Bessa, C., Dias, A. C. P., & Maciel, P. (2021). Neurotherapeutic effect of Hyptis spp. leaf extracts in Caenorhabditis elegans models of tauopathy and polyglutamine disease: Role of the glutathione redox cycle. Free Radical Biology & Medicine, 162, 202–215. https://doi.org/10.1016/j.freeradbiomed.2020.10.018
9 – Vilasboas-Campos, D., Costa, M. D., Teixeira-Castro, A., Rios, R., Silva, F. G., Aierken, A., Zhang, X., Bessa, C., Dias, A. C. P., & Maciel, P. (2020). Data on the effects of Hyptis spp. and Lycium spp. plant extracts in C. elegans models of genetically determined neurodegenerative diseases. Data in Brief, 33, 106598. https://doi.org/10.1016/j.dib.2020.106598
10 – Figueiredo, F., Sárkány, Z., Silva, A., Vilasboas-Campos, D., Maciel, P., Teixeira-Castro, A., Martins, P. M., & Macedo-Ribeiro, S. (2023). Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation. Biomedicine & Pharmacotherapy, 165, 115258. https://doi.org/10.1016/j.biopha.2023.115258